These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 12180053)

  • 41. Effect of systematic empiric treatment with imipenem on the bacterial ecology in a burns unit.
    Le Floch R; Arnould JF; Pilorget A
    Burns; 2005 Nov; 31(7):866-9. PubMed ID: 16039784
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A clinical study of imipenem/cilastatin in the treatment of generalized and localized infections.
    Tigano F; D'Ambrosio FP; Angio LG
    J Chemother; 1989 Jul; 1(4 Suppl):638-40. PubMed ID: 16312569
    [No Abstract]   [Full Text] [Related]  

  • 43. Antibiotic resistance in children with recurrent or complicated urinary tract infection.
    Younis N; Quol K; Al-Momani T; Al-Awaisheh F; Al-Kayed D
    JNMA J Nepal Med Assoc; 2009; 48(173):14-9. PubMed ID: 19529052
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical evaluation of piperacillin in the urological field].
    Hayashida S; Kitajima K; Joko K
    Hinyokika Kiyo; 1983 Apr; 29(4):465-76. PubMed ID: 6563846
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.
    Kollef MH; Chastre J; Clavel M; Restrepo MI; Michiels B; Kaniga K; Cirillo I; Kimko H; Redman R
    Crit Care; 2012 Nov; 16(6):R218. PubMed ID: 23148736
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.
    Buckley MM; Brogden RN; Barradell LB; Goa KL
    Drugs; 1992 Sep; 44(3):408-44. PubMed ID: 1382937
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Carbapenems: a potent class of antibiotics.
    Nicolau DP
    Expert Opin Pharmacother; 2008 Jan; 9(1):23-37. PubMed ID: 18076336
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of a novel injectable cephalosporin, Cefclidin, on the experimental complicated urinary tract infections with urinary stones caused by Pseudomonas aeruginosa and Proteus mirabilis.
    Satoh M; Munakata K; Takeuchi H; Yoshida O
    Hinyokika Kiyo; 1994 Aug; 40(8):689-94. PubMed ID: 7942366
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections].
    Hou F; Wu G; Zheng B
    Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):589-93. PubMed ID: 11758237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study.
    de la Rubia J; Montesinos P; Martino R; Jarque I; Rovira M; Vázquez L; López J; Batlle M; de la Cámara R; Juliá A; Lahuerta JJ; Debén G; Díaz J; García R; Sanz MA
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):512-6. PubMed ID: 19285640
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Antibiotic treatment of complicated urinary tract infections].
    Peters HJ
    Z Arztl Fortbild (Jena); 1995 Jun; 89(3):279-86. PubMed ID: 7668016
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
    Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
    Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Spectrum of pathogens and resistance to antibiotics in urinary tract infections and the consequences for antibiotic treatment: study of urology inpatients with urinary tract infections (1994-2001)].
    Wagenlehner E; Niemetz A; Naber G
    Urologe A; 2003 Jan; 42(1):13-25. PubMed ID: 12574879
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Imipenem in acute lung infections and bacterial re-exacerbations of chronic obstructive lung disease.
    Pozzi E; De Rose V
    J Chemother; 1991 Jan; 3 Suppl 1():213-7. PubMed ID: 12041768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [An imipenem-cilastatin combination in the treatment of infection at general intensive care units].
    Gouin F
    Presse Med; 1990 Apr; 19(13):620-4. PubMed ID: 2139943
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro activity of ertapenem: review of recent studies.
    Wexler HM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Imipenem/cilastatin sodium/relebactam fixed combination to treat urinary infections and complicated intra-abdominal bacterial infections.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2020 Apr; 56(4):241-255. PubMed ID: 32309820
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.